



ASX Release

Acrux webinar

Melbourne, Australia; 16 December 2024

Acrux Limited (ASX:ACR, “Acrux” or the “Company”) will host an Investor Webinar at 4.00pm (AEDT) on Tuesday 17 December and management will provide an update on the commercialisation of Nitroglycerin 0.4%, Ointment and a presentation to shareholders and investors.

Webinar details:

Date: Tuesday 17 December 2024

Time: 4.00pm Melbourne, Sydney, Canberra, Hobart
3.30pm Adelaide
3.00pm Brisbane
1.00pm Perth
6.00pm New Zealand

Topic: Acrux Investor Webinar

Please click on this link to join the webinar:

<https://us02web.zoom.us/j/83554655268>

Webinar ID: 835 5465 5268

Phone one-tap:

+61731853730,,83554655268# Australia

+61861193900,,83554655268# Australia

+6498846780,,83554655268# New Zealand

Other Australian and international numbers are available at:

International numbers available: <https://us02web.zoom.us/j/kc8BVwvPI>

Approved for release by the Managing Director of Acrux Limited.



For more information, please contact:

Michael Kotsanis
Acrux Limited
CEO & Managing Director

P: + 61 3 8379 0100
E: michael.kotsanis@acrux.com.au

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities.

For further information on Acrux, visit www.acrux.com.au